Valuation: Shield Therapeutics plc

Market Cap 50.29M 67.33M 58.62M 55.37M 94.2M 6.46B 94.52M 661M 255M 3.28B 253M 247M 10.57B P/E 2026 *
313x
P/E 2027 * 6.33x
Enterprise Value 68.74M 92.03M 80.14M 75.68M 129M 8.83B 129M 904M 349M 4.49B 345M 338M 14.44B EV / Sales 2026 *
1.29x
EV / Sales 2027 * 0.98x
Free-Float
38.25%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Shield Therapeutics plc

1 week+0.86%
Current month-22.95%
1 month+6.82%
3 months-27.69%
6 months-38.96%
Current year-52.28%
1 week 4.4
Extreme 4.4
4.9
1 month 4.4
Extreme 4.4
6.4
Current year 3.7
Extreme 3.7
12.5
1 year 3.7
Extreme 3.7
12.5
3 years 1.06
Extreme 1.0625
12.85
5 years 1.06
Extreme 1.0625
52
10 years 1.06
Extreme 1.0625
202
Manager TitleAgeSince
Chief Executive Officer 64 23/07/2024
Director of Finance/CFO 50 31/08/2026
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 68 31/01/2016
Chairman 70 17/06/2020
Director/Board Member 59 25/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
14/10/25 Free

Chief Executive Officer

1,547,262 0.1485%
13/02/25 Free

Chief Executive Officer

5,000,000 0.4800%
13/02/25 Buy

Chief Executive Officer

575,000 0.0552%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.86%-41.25%-55.24% 67.26M
-0.58%+0.43%+32.58%-6.20% 78.37B
-2.55%+6.99%+510.30%+44.31% 61.5B
-1.11%+5.08%-11.48%-33.39% 59.78B
+0.14%-1.20%-11.21%+24.73% 46.53B
-0.24%+1.22%+2.36%+154.40% 45.5B
-1.62%-0.76%+51.23%-16.04% 31.84B
-1.81%+3.16%+44.82%+106.78% 25.4B
+0.47%+3.26%+4.94%+144.25% 21.43B
+0.27%+1.96%+59.19%+106.18% 15.77B
Average -0.70%+2.07%+64.15%+46.98% 38.62B
Weighted average by Cap. -0.92%+2.35%+94.88%+39.83%

Financials

2026 *2027 *
Net sales 53.48M 71.61M 62.35M 58.88M 100M 6.87B 101M 704M 272M 3.49B 269M 263M 11.24B 69.92M 93.61M 81.51M 76.98M 131M 8.98B 131M 920M 355M 4.56B 351M 344M 14.69B
Net income 258K 345K 301K 284K 483K 33.12M 485K 3.39M 1.31M 16.84M 1.3M 1.27M 54.21M 7.74M 10.37M 9.03M 8.53M 14.51M 994M 14.55M 102M 39.34M 506M 38.91M 38.08M 1.63B
Net Debt 18.45M 24.71M 21.51M 20.32M 34.57M 2.37B 34.68M 243M 93.75M 1.2B 92.72M 90.74M 3.88B 18M 24.1M 20.98M 19.82M 33.71M 2.31B 33.83M 237M 91.44M 1.17B 90.44M 88.5M 3.78B
Logo Shield Therapeutics plc
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Employees
61
Date Price Change Volume
18/09/26 GBX 4.700 0.00% 755,157
17/09/26 GBX 4.700 +3.30% 1,376,397
16/09/26 GBX 4.550 +1.11% 1,646,105
15/09/26 GBX 4.500 -3.23% 1,446,321
14/09/26 GBX 4.650 -0.21% 2,414,100
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0470GBP
Average target price
0.1667GBP
Spread / Average Target
+254.62%

Annual profits - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!